ABSTRACT
Intrathecal baclofen administration is the reference treatment for spasticity of spinal or cerebral origin, but the risk of infection or catheter dysfunctions are important limits. To explore the possibility of alternative administration routes, we studied a new preparation comprising solid lipid nanoparticles (SLN) incorporating baclofen (baclofen-SLN). We used SLN because they are able to give a sustained release and to target the CNS. Wistar rats were injected intraperitoneally with baclofen-SLN or baclofen solution (baclofen-sol group) at increasing dosages. At different times up to 4 h, efficacy was tested by the H-reflex and two scales evaluating sedation and motor symptoms due to spinal lesions. Rats were killed and baclofen concentration determined in blood and tissues. Physiological solution or unloaded SLN was used as controls. After baclofen-SLN injection, the effect, consisting in a greater and earlier reduction of the H/M ratio than baclofen-sol group and controls, was statistically significant from a dose of 5 mg/kg and was inversely correlated with dose. Clinical effect of baclofen-SLN on both the behavioral scales was greater than that of baclofen-sol and lasted until 4th hour. Compared with baclofen-sol, baclofen-SLN produced significantly higher drug concentrations in plasma from 2nd hour until 4th hour with a linear decrement and in the brain at all times. In conclusion, our study demonstrated the efficacy of a novel formulation of baclofen, which exploits the advantages of SLN preparations. However, for clinical purposes, high baclofen concentrations in brain tissue and sedation may be unwanted effects, requiring further studies and optimization of dosages.
Subject(s)
Baclofen/pharmacokinetics , Drug Delivery Systems , Lipids/chemistry , Muscle Relaxants, Central/pharmacokinetics , Nanoparticles/chemistry , Animals , Baclofen/administration & dosage , Baclofen/chemistry , Baclofen/pharmacology , Behavior, Animal , Drug Carriers , Drug Compounding , Drug Evaluation, Preclinical , H-Reflex/physiology , Injections, Intraperitoneal , Lipids/administration & dosage , Male , Muscle Relaxants, Central/administration & dosage , Muscle Relaxants, Central/chemistry , Muscle Relaxants, Central/pharmacology , Muscle Spasticity/drug therapy , Muscle Spasticity/pathology , Nanoparticles/administration & dosage , Rats , Rats, Wistar , Tissue DistributionABSTRACT
Standard treatment for inflammatory bowel diseases (IBD) necessitates frequent intake of anti-inflammatory and/or immunosuppressive drugs, leading to significant adverse events. To evaluate the role solid lipid nanoparticles (SLN) play as drug delivery system in enhancing anti-inflammatory activity for drugs such as dexamethasone and butyrate in a human inflammatory bowel diseases whole-blood model. ELISA assay and the peripheral blood mononuclear cell (PBMC) cytokine mRNA expression levels were evaluated by quantitative SYBR Green real-time RT-PCR to determine the IL-1beta, TNF-alpha, IFN-gamma and IL-10 secretion in inflammatory bowel diseases patients' PBMC culture supernatants. There was a significant decrease in IL-1beta (p<0.01) and TNF-alpha (p<0.001) secretion, whilst IL-10 (p<0.05) secretion significantly increased after cholesteryl butyrate administration, compared to that of butyrate alone at the highest concentration tested (100 microM), at 24h exposure. There was a significant decrease in IL-1beta (p<0.01), TNF-alpha (p<0.001) and IL-10 (p<0.001) secretion after dexamethasone loaded SLN administration, compared to dexamethasone alone at the highest concentration tested (250 nM) at 24h exposure. No IFN-gamma was detected under any conditions and no cytotoxic effects observed even at the highest concentration tested. The incorporation of butyrate and dexamethasone into SLN has a significant positive anti-inflammatory effect in the human inflammatory bowel disease whole-blood model.
Subject(s)
Anti-Inflammatory Agents/administration & dosage , Inflammatory Bowel Diseases/drug therapy , Lipids/administration & dosage , Nanoparticles , Anti-Inflammatory Agents/therapeutic use , Chromatography, High Pressure Liquid , Cytokines/blood , Cytokines/genetics , Enzyme-Linked Immunosorbent Assay , Female , Humans , Inflammatory Bowel Diseases/blood , Male , Reverse Transcriptase Polymerase Chain Reaction , Spectrophotometry, UltravioletABSTRACT
Melatonin is a potent antioxidant molecule with a capacity to protect tissues from damage caused by oxidative stress. It reduces cyclosporine A (CsA)-induced cardiotoxicity; this improvement required melatonin's binding to its membrane receptors. This experimental study examined whether melatonin is a useful tool for counteracting CsA-induced apoptosis in the heart of rats. We investigated melatonin's antiapoptotic efficacy in protecting the heart and tested whether this effect was totally dependent on its binding to membrane receptors or also involved radical scavenging. In some animals, solid lipid nanoparticles (SLN) as a melatonin delivery system were used. In one group of rats, melatonin (1 mg/kg/day i.p.) was given concurrently with CsA (15 mg/kg/day s.c.; CsA-MT) for 21 days. In other animals, melatonin loaded in SLN was injected with CsA (CsA-MTSLN). Oxidative stress in heart tissue was estimated using the evaluation of lipid peroxidation and the expression of the isoform of inducible nitric oxide (iNOS). The antiapoptotic effect of melatonin was evaluated using TUNEL staining and Bcl-2 protein family expression. CsA administration produced morphological and biochemical changes in the heart of rats, while melatonin reversed the changes. In particular, since the antiapoptotic melatonin's efficacy is mainly observed when it is loaded in SLN, we suggest that MT1/MT2 pathway is not sufficient for apoptosis antagonism and the additional intracellular effects may be required. Finally, we show that, (i) melatonin significantly reduces CsA cardiotoxicity acting also on apoptotic processes, and (ii) the reduction in CsA-induced cardiotoxicity is mediated mainly by its antioxidant effect.
Subject(s)
Cyclosporine/toxicity , Heart Diseases/chemically induced , Heart Diseases/prevention & control , Immunosuppressive Agents/toxicity , Melatonin/administration & dosage , Nanoparticles/administration & dosage , Analysis of Variance , Animals , Apoptosis/drug effects , Drug Carriers , In Situ Nick-End Labeling , Lipid Peroxidation/drug effects , Lipids/administration & dosage , Lipids/therapeutic use , Male , Malondialdehyde/metabolism , Melatonin/metabolism , Melatonin/therapeutic use , Myocardium/ultrastructure , Nanoparticles/therapeutic use , Nitric Oxide Synthase Type II/metabolism , Oxidative Stress/drug effects , Proto-Oncogene Proteins c-bcl-2/metabolism , Rats , Rats, WistarABSTRACT
The chapter examined solid lipid nanoparticles (SLN) and microemulsions, chosen as carriers of drugs, administered in vivo to be transported to the central nervous system. Drugs of different structures and for different therapies have been studied such as doxorubicin SLN stealth and nonstealth administered in rats by intravenous route, apomorphine SLN administered in rats by duodenal route, melatonin SLN administered by transdermal and oral routes in humans, and apomorphine microemulsion administered by transdermal route in Parkinson's patients. The pharmacokinetics of the drug, followed in most studies, put in evidence that the many important pharmacokinetic parameters were notably improved versus the drug alone or in a commercial formulation.
Subject(s)
Drug Delivery Systems/methods , Emulsions/pharmacokinetics , Lipids/pharmacokinetics , Nanoparticles/chemistry , Nanoparticles/therapeutic use , Nanotechnology/methods , Administration, Cutaneous , Administration, Oral , Animals , Chemistry, Pharmaceutical/methods , Chemistry, Pharmaceutical/trends , Drug Compounding/methods , Drug Compounding/trends , Drug Delivery Systems/trends , Emulsions/chemical synthesis , Humans , Lipids/chemical synthesis , Models, Animal , Nanotechnology/trends , RatsABSTRACT
Malignant gliomas, despite aggressive multimodal therapies and adequate supportive care, still maintain poor prognosis. Solid lipid nanoparticles (SLN) are colloidal carriers that could be regarded as a highly flexible platform for brain tumor imaging and therapeutical purposes. In this chapter we will first describe brain tumors characteristics and conventional therapeutical approaches. In the subsequent sections, we will analyze SLN properties, effectiveness, and future perspectives in both imaging and targeted treatment of malignant gliomas.
Subject(s)
Antineoplastic Agents/administration & dosage , Brain Neoplasms/drug therapy , Lipids/pharmacokinetics , Nanoparticles/therapeutic use , Nanotechnology/methods , Neuropharmacology/methods , Animals , Antineoplastic Agents/pharmacokinetics , Blood-Brain Barrier/drug effects , Blood-Brain Barrier/metabolism , Disease Models, Animal , Humans , Lipids/chemical synthesis , Medical Oncology/methods , Nanoparticles/chemistry , Nanoparticles/toxicity , Nanotechnology/trends , Neurochemistry/methods , Neurochemistry/trends , Neuropharmacology/trends , RatsABSTRACT
Cholesterylbutyrate (Chol-but) was chosen as a prodrug of butyric acid. Butyrate is not often used in vivo because its half-life is very short and therefore too large amounts of the drug would be necessary for its efficacy. In the last few years butyric acid's anti-inflammatory properties and its inhibitory activity towards histone deacetylases have been widely studied, mainly in vitro. Solid Lipid Nanoparticles (SLNs), whose lipid matrix is Chol-but, were prepared to evaluate the delivery system of Chol-but as a prodrug and to test its efficacy in vitro and in vivo. Chol-but SLNs were prepared using the microemulsion method; their average diameter is on the order of 100-150 nm and their shape is spherical. The antineoplastic effects of Chol-but SLNs were assessed in vitro on different cancer cell lines and in vivo on a rat intracerebral glioma model. The anti-inflammatory activity was evaluated on adhesion of polymorphonuclear cells to vascular endothelial cells. In the review we will present data on Chol-but SLNs in vitro and in vivo experiments, discussing the possible utilisation of nanoparticles for the delivery of prodrugs for neoplastic and chronic inflammatory diseases.
Subject(s)
Cholesterol Esters/chemistry , Cholesterol Esters/pharmacology , Lipids/chemistry , Nanoparticles/chemistry , Prodrugs/chemistry , Animals , Cell Death/drug effects , Humans , Lipids/pharmacology , Prodrugs/pharmacologyABSTRACT
Nanovector was founded in 2001 and is one of the companies that first began working in the nanomedicine field in Italy, having a specific focus on developing its technical platform for drug-delivery applications. Proprietary lipid nanocarriers, microemulsions and Solid Lipid Nanoparticles have been tested over recent years, delivering different drugs by different administration routes: in this profile, a short overview of our main results will be given. The delivery system platform has shown and confirmed promising characteristics. Focusing on solid lipid nanoparticles, a leading possibility as a carrier for hydrophobic and hydrophilic drugs, we have tested four administration routes (intravenous, oral/duodenal, eye topical and transdermal), their rapid internalization into cells, their in vivo targeting to areas not usually reached (brain and eye posterior globe) and their ability to cross the intestinal mucosa, thus enabling administration of drugs from intravenous to oral. Nanovector aims to exploit the proprietary technical platform to develop therapeutics in areas with strong unmet medical needs and promising market opportunities.
Subject(s)
Chemistry, Pharmaceutical/trends , Drug Delivery Systems/trends , Drug Industry/trends , Nanomedicine/trends , Nanostructures/therapeutic use , ItalySubject(s)
Drug Delivery Systems , Nanoparticles , Animals , Drug Administration Routes , Drug Stability , Humans , LipidsABSTRACT
OBJECTIVES: Brain malignant neoplasms are still characterized by poor prognosis due to their peculiar hallmarks that severely limit aggressive multimodal therapeutic approaches. The optimization of the intratumoral drug delivery, directed to achieve effective concentrations and to reduce systemic undesired toxicity, is one of the primary goals of the brain tumors therapeutic strategies. Different passive and active delivery carriers allowing to a better control of drug distribution, metabolism, and elimination after parenteral administration have been developed. In the present review we will describe general characteristics and evaluate the efficacy of Solid Lipid Nanoparticles (SLN) as carriers of different drugs in experimental brain malignant tumor therapy. METHODS: SLN vehiculating different illustrative types of antineoplastic agents (conventional cytotoxic drugs such as doxorubicin and paclitaxel, the prodrug Cholesteryl butyrate, and anti VEGF antisense oligonucleotides) have been tested in experimental animal models of cerebral gliomas. RESULTS: SLN proved to successfully vehiculate into the brain different types of cytotoxic and gene therapeutical agents (otherwise unable to pass through the Blood-Brain Barrier) and to induce effective anti-tumoral therapeutical response. DISCUSSION: Compared to other vehicules, SLN seem to offer more advantages (such as higher physical stability, greater protection from degradation and better release profile of incorporated drugs, good tolerability and possibility of site-specific targeting) and could be regarded as an effective carrier for chemotherapeutic drugs, gene therapeutical agents, and diagnostic tools in neuro-oncology.
Subject(s)
Brain Neoplasms/drug therapy , Drug Delivery Systems , Nanoparticles/therapeutic use , Animals , Antineoplastic Agents/therapeutic use , Combined Modality Therapy , HumansABSTRACT
melatonin (MT) is a hormone produced by the pineal gland at night, involved in the regulation of circadian rhythms. For clinical purposes, exogenous MT administration should mimic the typical nocturnal endogenous MT levels, but its pharmacokinetics is not favourable due to short half-life of elimination. Aim of this study is to examine pharmacokinetics of MT incorporated in solid lipid nanoparticles (SLN), administered by oral and transdermal route. SLN peculiarity consists in the possibility of acting as a reservoir, permitting a constant and prolonged release of the drugs included. In 7 healthy subjects SLN incorporating MT 3 mg (MT-SLN-O) were orally administered at 8.30 a.m. MT 3 mg in standard formulation (MT-S) was then administered to the same subjects after one week at 8.30 a.m. as controls. In 10 healthy subjects SLN incorporating MT were administered transdermally (MT-SLN-TD) by the application of a patch at 8.30 a.m. for 24 hours. Compared to MT-S, Tmax after MT-SLN-O administration resulted delayed of about 20 minutes, while mean AUC and mean half life of elimination was significantly higher (respectively 169944.7 +/- 64954.4 pg/ml x hour vs. 85148.4 +/- 50642.6 pg/ml x hour, p = 0.018 and 93.1 +/- 37.1 min vs. 48.2 +/- 8.9 min, p = 0.009). MT absorption and elimination after MT-SLN-TD demonstrated to be slow (mean half life of absorption: 5.3 +/- 1.3 hours; mean half life of elimination: 24.6 +/- 12.0 hours), so MT plasma levels above 50 pg/ml were maintained for at least 24 hours. This study demonstrates a significant absorption of MT incorporated in SLN, with detectable plasma level achieved for several hours in particular after transdermal administration. As dosages and concentrations of drugs included in SLN can be varied, different plasma level profile could be obtained, so disclosing new possibilities for sustained delivery systems.
Subject(s)
Delayed-Action Preparations/chemistry , Drug Carriers/chemistry , Lipids/chemistry , Liposomes/chemistry , Melatonin/administration & dosage , Melatonin/pharmacokinetics , Nanostructures/chemistry , Administration, Cutaneous , Administration, Oral , Chemistry, Pharmaceutical/methods , Delayed-Action Preparations/administration & dosage , Delayed-Action Preparations/pharmacokinetics , Diffusion , Drug Carriers/administration & dosage , Drug Carriers/pharmacokinetics , Humans , Melatonin/chemistry , Metabolic Clearance Rate , Nanostructures/ultrastructure , Particle SizeABSTRACT
The structure of both carrier and anticancer drug affects the intracellular fate of a transported drug. The study investigated in vitro intracellular accumulation and cytotoxic activity of doxorubicin-loaded solid lipid nanoparticles (SLN), doxorubicin in pegylated liposomes (Caelyx) and free doxorubicin. Intracellular doxorubicin levels and cytotoxic activity were determined by high performance liquid chromatography with fluorescence detection, and by the trypan blue dye exclusion assay, respectively. Doxorubicin-loaded SLN inhibited cell growth more strongly than either free or liposomal doxorubicin, in human colorectal adenocarcinoma, HT-29, retinoblastoma Y79, and glioblastoma U373 cell lines. The IC50 values for doxorubicin-loaded SLN were significantly lower after 24 h exposure than those for free doxorubicin in all cell lines; after 48 h exposure they were lower than those for liposomal doxorubicin in HT-29 and Y79 cells. The enhanced cytotoxic activity of doxorubicin-loaded SLN was associated with increased drug incorporation in cells: intracellular doxorubicin levels were significantly enhanced after exposure to drug-loaded SLN versus either free or liposomal drug. Rate of intracellular accumulation and cytotoxic activity also differed among different cell lines; in particular, cells of epithelial origin were found to be more sensitive to doxorubicin-loaded SLN. In conclusion, the greater sensitivity of HT-29, Y79, and U373 cells to doxorubicin-loaded SLN than to the other drug formulations may be due to the capability of the delivery system to enhance drug action, through a marked uptake and accumulation of SLN within the cell.
Subject(s)
Doxorubicin/administration & dosage , Doxorubicin/pharmacokinetics , Drug Carriers/chemistry , Liposomes/chemistry , Neoplasms/metabolism , Neoplasms/pathology , Polyethylene Glycols/chemistry , Antibiotics, Antineoplastic/administration & dosage , Antibiotics, Antineoplastic/pharmacokinetics , Cell Line, Tumor , Cell Survival/drug effects , Dose-Response Relationship, Drug , Humans , Intracellular Fluid/metabolism , Nanostructures/chemistry , Nanostructures/ultrastructureABSTRACT
As people grow old, their need for medications increases dramatically because of the higher incidence of chronic pain, diabetes mellitus, cardiovascular and neurological diseases in the elderly population. Furthermore, the elderly require special consideration with respect to drug delivery, drug interactions and adherence. In particular, patients with chronic neurological diseases often require multiple administration of drugs during the day to maintain constant plasma medication levels, which in turn increases the likelihood of poor adherence. Consequently, several attempts have been made to develop pharmacological preparations that can achieve a constant rate of drug delivery. For example, transdermal lisuride and apomorphine have been shown to reduce motor fluctuations and duration of 'off' periods in advanced Parkinson's disease, while rotigotine allows significant down-titration of levodopa without severe adverse effects. Thus, parkinsonian patients with long-term levodopa syndrome or motor disorders during sleep could benefit from use of transdermal lisuride and apomorphine. Moreover, transdermal dopaminergic drugs, particularly rotigotine, seem the ideal treatment for patients experiencing restless legs syndrome or periodic limb movement disorder during sleep, disorders that are quite common in elderly people or in association with neurodegenerative diseases. Unlike dopaminergic drugs, transdermal treatments for the management of cognitive and behavioural dysfunction in patients with Parkinson's disease and Alzheimer's disease have inconsistent effects and no clearly established role. Nevertheless, because of their favourable pharmacological profile and bioavailability, the cholinesterase inhibitors tacrine and rivastigmine are expected to show at least the same benefits as oral formulations of these drugs, but with fewer severe adverse effects. Transdermal delivery systems play an important role in the management of neuropathic pain. The transdermal lidocaine (lignocaine) patch is recommended as first-line therapy for the treatment of postherpetic neuralgia. Furthermore, in patients with severe persistent pain, transdermal delivery systems using the opioids fentanyl and buprenorphine are able to achieve satisfactory analgesia with good tolerability, comparable to the benefits seen with oral formulations. Transdermal administration is the ideal therapeutic approach for chronic neurological disorders in elderly people because it provides sustained therapeutic plasma levels of drugs, is simple to use, and may reduce systemic adverse effects. Several transdermal delivery systems are currently under investigation for the treatment of Parkinson's disease, Alzheimer's disease and neuropathic pain. Although most transdermal delivery systems treatments cannot be considered as first-line therapy at present, some of them provide clear advantages compared with other routes of administration and may become the preferred treatment in selected patients. In general, however, most transdermal treatments still require long-term evaluation in large patient groups in order to optimise dosages and evaluate the actual incidence of local and systemic adverse effects.
Subject(s)
Nervous System Diseases/drug therapy , Administration, Cutaneous , Aged , Aging , Alzheimer Disease/drug therapy , Analgesics, Opioid/therapeutic use , Cognition , Dopamine/metabolism , Drug Delivery Systems , Estrogens/metabolism , Humans , Parkinson Disease/drug therapyABSTRACT
1. Adhesion of polymorphonuclear cells (PMNs) to vascular endothelial cells (EC) is a critical step in recruitment and infiltration of leukocytes into tissues during inflammation. High doses of butyric acid have been shown to ameliorate inflammation in inflammatory bowel diseases (IBD). Cholesteryl-butyrate solid lipid nanoparticles (chol-but SLN) as prodrug are a possible delivery system for butyric acid. 2. Sodium butyrate or chol-but SLN were coincubated with human PMNs and human umbilical vein EC (HUVEC); adhesion was quantified by computerized microimaging fluorescence analysis. Both chol-but SLN and sodium butyrate displayed antiadhesive effects on FMLP- and IL-1beta-stimulated cells in a concentration-response curve (10(-8)-10(-5) M), but chol-but SLN were in all cases more active. Moreover, chol-but SLN inhibited FMLP-induced adhesion of PMNs to FCS-coated plastic wells, thus showing a direct effect on PMNs, while sodium butyrate had little effect. Confocal microscopy showed that fluorescent SLN entered PMNs and HUVEC after 10 min incubation. Chol-but SLN acted either on activated PMN or HUVEC. 3. Chol-but SLN inhibited O2-* production and myeloperoxidase release by PMNs evoked by FMLP, in a dose-dependent, but not time-dependent, manner and were more active than sodium butyrate. 4. In conclusion, in all tests chol-but SLN were more active than sodium butyrate. Thus, chol-but SLN might be a valid alternative to sodium butyrate in the anti-inflammatory therapy of ulcerative colitis, avoiding complications related to the administration of sodium butyrate.
Subject(s)
Butyrates/pharmacology , Cell Adhesion/drug effects , Cholesterol Esters/pharmacology , Endothelial Cells/drug effects , Nanoparticles , Neutrophils/drug effects , Cell Survival/drug effects , Cells, Cultured , Humans , Interleukin-1beta/pharmacology , Lipids/pharmacology , N-Formylmethionine Leucyl-Phenylalanine/pharmacology , Nanoparticles/chemistry , Peroxidase/metabolism , Superoxides/metabolismABSTRACT
We studied absorption, efficacy, and tolerability in Parkinson's disease (PD) of a new preparation of apomorphine included in a microemulsion and administered by transdermal route (Apo-MTD). Twenty-one PD patients were treated with levodopa plus oral dopamine-agonists (T0), with levodopa alone (T1), finally with levodopa plus Apo-MTD (T2). Apo-MTD provided therapeutic plasma levels for many hours, improved Unified Parkinson's Disease Rating Scale III scores, and reduced total duration of off periods compared to T0 and T1. We concluded that Apo-MTD is absorbed and demonstrates clinical efficacy and long action. Therefore, it seems a promising add-on treatment for uncontrolled prolonged off phases in PD patients, but chronic tolerability needs further study.
Subject(s)
Administration, Cutaneous , Antiparkinson Agents/therapeutic use , Apomorphine/therapeutic use , Parkinson Disease/drug therapy , Aged , Antiparkinson Agents/blood , Apomorphine/blood , Area Under Curve , Drug Therapy, Combination , Emulsions , Female , Humans , Levodopa/therapeutic use , Male , Middle Aged , Parkinson Disease/blood , Severity of Illness Index , Time FactorsABSTRACT
Cholesteryl butyrate solid lipid nanoparticles (chol-but SLN) have been proposed as a pro-drug to deliver butyric acid. We compared the effects on cell growth, cell-cycle distribution and c-myc expression of chol-but SLN and sodium butyrate (Na-but) in the human leukemic cell lines Jurkat, U937 and HL-60. In all the cell lines 0.5 and 1.0 mM chol-but SLN provoked a complete block of cell growth. Cell-cycle analysis demonstrated in Jurkat cells that 0.25 mM chol-but SLN caused a pronounced increase of G2/M cells and a decrease of G0/G1 cells, whereas in U937 and HL-60 cells chol-but SLN led to a dose-dependent increase of G0/G1 cells, with a decrease of G2/M cells. In Jurkat and HL-60 cells 0.5 mM chol-but SLN induced a significant increase of sub-G0/G1 apoptotic cells. Cell growth and cell-cycle distribution were unaffected by the same concentrations of Na-but. A concentration of 0.25 mM chol-but SLN was able to cause a rapid and transient down-regulation of c-myc expression in all the cell lines, whereas 1 mM Na-but caused a slight reduction of c-myc expression only in U937 cells. The results show how chol-but SLN affects the proliferation pattern of both myeloid and lymphoid cells to an extent greater than the natural butyrate.
Subject(s)
Butyrates/pharmacology , Cholesterol Esters/pharmacology , Phosphatidylcholines/chemistry , Prodrugs/pharmacology , Proto-Oncogene Proteins c-myc/biosynthesis , Apoptosis/drug effects , Blotting, Western , Butyrates/administration & dosage , Butyrates/chemistry , Cell Cycle/drug effects , Cell Proliferation/drug effects , Cell Survival/drug effects , Cholesterol Esters/chemistry , HL-60 Cells , Humans , Jurkat Cells , Microscopy, Fluorescence , Nanotechnology , Particle Size , Reverse Transcriptase Polymerase Chain Reaction , Time Factors , U937 CellsABSTRACT
An apparatus to dry aqueous dispersions of solid lipid nanoparticles (SLNs) was designed. Optimal running conditions were evaluated to obtain minimum process time and produce dried SLNs characterized by small size variation. To achieve process optimization, SLN average diameter, SLNs polydispersity index, and drying time were related to three operative variables: process temperature, SLN concentration in the original aqueous dispersions, and nitrogen flow rate as the physical means of the drying process. An experimental design procedure and a multicriteria optimization method, targeting desirability functions, enabled us to obtain the optimal conditions for all responses. Drying time, average diameter, and polydispersity index of dried SLN batches were more favorable than those obtained by freeze-drying identical SLN aqueous dispersions with the same initial nanoparticle concentration.
Subject(s)
Lipids/chemistry , Nanotechnology/methods , Water/chemistry , Freeze Drying/instrumentation , Freeze Drying/methods , Nanotechnology/instrumentationABSTRACT
Solid Lipid Nanoparticles (SLN) are already under investigation as a pharmaceutical tool able to change the pharmacokinetic and biodistribution of carried molecules. SLN are able to target drugs to lymph after duodenal administration and to overcome the Blood Brain Barrier (BBB). In this study, superparamagnetic SLN have been prepared, have colloidal size, in vitro analysis showed relaxometric properties similar to Endorem. In vivo Magnetic Resonance Imaging (MRI) of the central nervous system (CNS) with both SLN and Endorem showed that superparamagnetic SLN have slower blood clearance than Endorem. MRI data are consistent with CNS uptake of SLN lasting up to the end of the experiment (135 min). These findings confirm the ability of SLN to overcome the BBB; SLN might be used as a CNS MRI contrast agent.
Subject(s)
Iron/administration & dosage , Lipids/administration & dosage , Nanotechnology/methods , Oxides/administration & dosage , Animals , Blood-Brain Barrier/drug effects , Blood-Brain Barrier/physiology , Brain/drug effects , Brain/metabolism , Chemistry, Pharmaceutical , Ferrosoferric Oxide , Iron/pharmacokinetics , Lipids/pharmacokinetics , Magnetic Resonance Imaging/methods , Oxides/pharmacokinetics , Rats , Rats, Sprague-DawleyABSTRACT
Three types of solid lipid nanoparticles (SLN) containing three different percentages of tobramycin (1.25, 2.50, 5.00%) were prepared (Tobra-SLN), and the in vitro tobramycin diffusion through a hydrophilic/lipophilic membrane was determined. A variable quantity of each of the three SLN types was placed in the donor compartment to achieve the same amount of tobramycin in each case. Tobramycin diffusion varied with the percentage of drug incorporated in SLN: the higher the percentage of tobramycin incorporated, the greater the amount of the drug diffused. In vivo uptake and transport were determined after administering a fixed dose of tobramycin (5 mg/kg) in each of the three types of SLN intraduodenally to rats. At fixed times, blood was sampled from the jugular vein and lymph from the thoracic duct. Lymph and blood were examined by transmission electron microscopy (TEM) analysis to detect the presence, sizes, and shape of SLN. The pharmacokinetic parameters varied considerably with the type of Tobra-SLN: the area under the curve of plasma concentration versus time (AUC) of 1.25% Tobra-SLN was more than five times higher than that of 5.00% Tobra-SLN; the longest residence time was obtained with 1.25% Tobra-SLN; and the clearance of 5.00% Tobra-SLN was fivefold than that of 1.25% Tobra-SLN. This behavior may be related to the differences among the three types of SLN; namely, the number of SLN administered and the mean diameter, the total surface area, and the drug content in each nanoparticle. TEM analysis showed that Tobra-SLNs were targeted to the lymph. Tobra-SLN may act as a reservoir of the drug in the lymphatic system, thereby favoring its sustained release.
Subject(s)
Anti-Bacterial Agents/metabolism , Duodenum/metabolism , Tobramycin/metabolism , Absorption , Animals , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/blood , Delayed-Action Preparations , Diffusion , Drug Delivery Systems , Emulsions , In Vitro Techniques , Lipids/administration & dosage , Lymph/metabolism , Lymph Nodes/metabolism , Male , Microscopy, Electron , Nanotechnology , Particle Size , Rats , Rats, Wistar , Time Factors , Tobramycin/administration & dosage , Tobramycin/bloodABSTRACT
The pharmacokinetics and tissue distribution of doxorubicin incorporated in non-stealth solid lipid nanoparticles (SLN) and in stealth solid lipid nanoparticles (SSLN) (three formulations at increasing concentrations of stearic acid-PEG 2000 as stealth agent) after intravenous administration to conscious rabbits have been studied. The control was the commercial doxorubicin solution. The experiments lasted 6 h and blood samples were collected at fixed times after the injections. In all samples, the concentration of doxorubicin and doxorubicinol were determined. Doxorubicin AUC increased as a function of the amount of stealth agent present in the SLN. Doxorubicin was still present in the blood 6 h after the injection of SLN or SSLN, while no doxorubicin was detectable after the i.v. injection of doxorubicin solution. Tissue distribution of doxorubicin was determined 30 min, 2 and 6 h after the administration of the five formulations. Doxorubicin was present in the brain only after the SLN administration. The increase in the stealth agent affected the doxorubicin transported into the brain; 6 h after injection, doxorubicin was detectable in the brain only with the SSLN at the highest amount of stealth agent. In the other rabbit tissues (liver, lungs, spleeen, heart and kidneys) the amount of doxorubicin present was always lower after the injection of any of the four types of SLN than after the commercial solution. In particular, all SLN formulations significantly decreased heart and liver concentrations of doxorubicin.
Subject(s)
Brain/drug effects , Doxorubicin/administration & dosage , Drug Carriers/administration & dosage , Nanotechnology/methods , Animals , Brain/metabolism , Chemistry, Pharmaceutical , Doxorubicin/blood , Doxorubicin/pharmacokinetics , Drug Carriers/pharmacokinetics , Injections, Intravenous , Microspheres , Rabbits , Tissue Distribution/drug effects , Tissue Distribution/physiologyABSTRACT
The cyclic undecapeptide cyclosporin A (CyA) a potent immunosuppressive drug used in many therapies, is extremely hydrophobic. Commercial products employ solubilising agents to improve gastrointestinal absorption. In the present study CyA solid lipid nanoparticles (SLN) are prepared from warm o/w microemulsion, dispersed in cold water. The matrix chiefly consists of stearic acid, phosphatidylcholine and taurocholate; up to 13% of CyA can be incorporated. The average diameter of CyA-loaded SLNs is below 300 nm and transmission electron microscopy (TEM) analysis shows them to be spherical. In vitro release of CyA from SLNs is low. CyA-loaded SLNs can be proposed for most administration routes, in particular for the duodenal route.